Blueprint Medicines Corp Stock Today

BPMC Stock  USD 94.79  5.12  5.71%   

Performance

2 of 100

 
Low
 
High
Weak

Odds Of Distress

Less than 38

 
100  
 
Zero
Below Average
Blueprint Medicines is trading at 94.79 as of the 28th of March 2024, a 5.71 percent up since the beginning of the trading day. The stock's open price was 89.67. Blueprint Medicines has about a 38 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Blueprint Medicines Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
30th of April 2015
Category
Healthcare
Classification
Health Care
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. The company has 61.23 M outstanding shares of which 5.15 M shares are currently shorted by private and institutional investors with about 5.33 trading days to cover. More on Blueprint Medicines Corp

Moving together with Blueprint Stock

  0.65MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Blueprint Stock

  0.65VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
  0.55TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr

Blueprint Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Blueprint Medicines' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Blueprint Medicines or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEO, DirectorJeffrey Albers
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Blueprint Medicines report their recommendations after researching Blueprint Medicines' financial statements, talking to executives and customers, or listening in on Blueprint Medicines' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Blueprint Medicines Corp. The Blueprint consensus assessment is calculated by taking the average forecast from all of the analysts covering Blueprint Medicines.
Financial Strength
Based on the key indicators related to Blueprint Medicines' liquidity, profitability, solvency, and operating efficiency, Blueprint Medicines Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Blueprint Medicines Corp is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.120.2377
Way Down
Slightly volatile
Gross Profit Margin1.020.9019
Moderately Up
Slightly volatile
Total Current Liabilities225.7 M214.9 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total738.9 M703.7 M
Sufficiently Up
Slightly volatile
Total Assets784.9 MB
Way Down
Slightly volatile
Total Current Assets548 M808.4 M
Way Down
Slightly volatile
Blueprint Medicines' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Blueprint Medicines' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Blueprint Medicines' financial leverage. It provides some insight into what part of Blueprint Medicines' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Blueprint Medicines' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Blueprint Medicines deploys its capital and how much of that capital is borrowed.
Liquidity
Blueprint Medicines cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 774.12 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Blueprint Medicines Corp has a current ratio of 5.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Blueprint Medicines until it has trouble settling it off, either with new capital or with free cash flow. So, Blueprint Medicines' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Blueprint Medicines Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Blueprint to invest in growth at high rates of return. When we think about Blueprint Medicines' use of debt, we should always consider it together with cash and equity.

Stock Based Compensation

47.05 Million
Blueprint Medicines Corp (BPMC) is traded on NASDAQ Exchange in USA. It is located in 45 Sidney Street, Cambridge, MA, United States, 02139 and employs 655 people. Blueprint Medicines is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.8 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Blueprint Medicines's market, we take the total number of its shares issued and multiply it by Blueprint Medicines's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Blueprint Medicines Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.23 M outstanding shares of which 5.15 M shares are currently shorted by private and institutional investors with about 5.33 trading days to cover. Blueprint Medicines Corp currently holds about 853.11 M in cash with (436.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28.
Check Blueprint Medicines Probability Of Bankruptcy
Ownership Allocation
Blueprint Medicines Corp retains a total of 61.23 Million outstanding shares. The majority of Blueprint Medicines Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Blueprint Medicines Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Blueprint Medicines. Please pay attention to any change in the institutional holdings of Blueprint Medicines Corp as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Blueprint Ownership Details

Blueprint Stock Price Odds Analysis

What are Blueprint Medicines' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Blueprint Medicines jumping above the current price in 90 days from now is about 7.14%. The Blueprint Medicines Corp probability density function shows the probability of Blueprint Medicines stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.1105 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Blueprint Medicines will likely underperform. Additionally, blueprint Medicines Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 94.79HorizonTargetOdds Above 94.79
92.80%90 days
 94.79 
7.14%
Based on a normal probability distribution, the odds of Blueprint Medicines to move above the current price in 90 days from now is about 7.14 (This Blueprint Medicines Corp probability density function shows the probability of Blueprint Stock to fall within a particular range of prices over 90 days) .

Blueprint Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Blueprint Medicines that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Blueprint Medicines' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Blueprint Medicines' value.
InstituionRecorded OnShares
Jpmorgan Chase & Co2023-12-31
1.5 M
Lord, Abbett & Co Llc2023-12-31
1.4 M
Alliancebernstein L.p.2023-12-31
1.4 M
Geode Capital Management, Llc2023-12-31
1.3 M
Morgan Stanley - Brokerage Accounts2023-12-31
1.2 M
Goldman Sachs Group Inc2023-12-31
1.2 M
Polar Capital Holdings Plc2023-12-31
865 K
Woodline Partners Lp2023-12-31
814.5 K
American Century Companies Inc2023-12-31
711.7 K
Blackrock Inc2023-12-31
6.6 M
Vanguard Group Inc2023-12-31
6.1 M
View Blueprint Medicines Diagnostics

Blueprint Medicines Historical Income Statement

Blueprint Medicines Corp Income Statement is one of the three primary financial statements used for reporting Blueprint's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Blueprint Medicines Corp revenue and expense. Blueprint Medicines Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Blueprint Medicines' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 293.8 M, whereas Other Operating Expenses is forecasted to decline to about 390 M. View More Fundamentals

Blueprint Stock Against Markets

Picking the right benchmark for Blueprint Medicines stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Blueprint Medicines stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Blueprint Medicines is critical whether you are bullish or bearish towards Blueprint Medicines Corp at a given time. Please also check how Blueprint Medicines' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Blueprint Medicines without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Blueprint Medicines Corporate Directors

Blueprint Medicines corporate directors refer to members of a Blueprint Medicines board of directors. The board of directors generally takes responsibility for the Blueprint Medicines' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Blueprint Medicines' board members must vote for the resolution. The Blueprint Medicines board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Nicholas LydonDirectorProfile
Michael LandsittelInterim Principal Accounting and Financial Officer and Sr. Director of Fin.Profile
George DemetriIndependent DirectorProfile
Alexis BorisyDirectorProfile

How to buy Blueprint Stock?

Before investing in Blueprint Medicines, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Blueprint Medicines. To buy Blueprint Medicines stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Blueprint Medicines. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Blueprint Medicines stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Blueprint Medicines Corp stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Blueprint Medicines Corp stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Blueprint Medicines Corp, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Blueprint Stock please use our How to Invest in Blueprint Medicines guide.

Already Invested in Blueprint Medicines Corp?

The danger of trading Blueprint Medicines Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Blueprint Medicines is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Blueprint Medicines. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Blueprint Medicines Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Blueprint Stock analysis

When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
CEOs Directory
Screen CEOs from public companies around the world
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.37)
Revenue Per Share
4.118
Quarterly Revenue Growth
0.855
Return On Assets
(0.25)
Return On Equity
(1.57)
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.